BOSTON, May 29 /PRNewswire-FirstCall/ -- Perceptive Informatics, the technology subsidiary of PAREXEL International Corporation , today announced the availability of a unique medical imaging capability, called the Double Reference Tissue Method (DRTM). Based upon magnetic resonance imaging (MRI), this technique helps to evaluate blood flow to tumors with increased precision. Certain compounds in clinical development to treat cancer have as their mechanism of action the ability to decrease blood supply to tumors. The Double Reference Tissue Method was developed by the University of Chicago and is being commercialized by Perceptive Informatics for the first uses by the bio/pharmaceutical industry in clinical development programs.
“This breakthrough medical imaging method will enable our clients, to make earlier and more informed decisions about their oncology studies,” said Jay Zimmerman, Vice President of Medical Imaging at Perceptive Informatics. “We value our collaboration with the University of Chicago, which represents the innovation that can be achieved when academic institutions and industry technology providers collaborate toward important advances.”
“DRTM will mean significant progress for clinical research since it produces higher quality data for greater visibility into drug activity,” said Dr. Cheng Yang, Professor in the Department of Medicine at the University of Chicago. “We are pleased that this new imaging method now has broader availability and benefit to the biopharmaceutical industry.”
The Double Reference Tissue Method is part of Perceptive Informatics’ portfolio of imaging techniques, used from early development through peri- approval studies. Perceptive’s Medical Imaging division has expertise in multiple therapeutic areas, as well as significant experience in the use of a wide range of imaging modalities including conventional radiography, computed tomography (CT), magnetic resonance imaging (MRI), ultrasound, angiography, and nuclear medicine including FDG PET (fluorodeoxyglucose positron emission tomography.
About Perceptive Informatics, a PAREXEL Company
PAREXEL’s Technology Division, Perceptive Informatics, combines clinical knowledge, quality and regulatory experience with advanced technology to decrease time to market, risk and cost associated with clinical trials. Perceptive’s portfolio includes Medical Imaging, Clinical Trial Management Systems (CTMS), Interactive Voice Response Systems (IVRS & IWRS), and Integration Services as well as web-based portal solutions, tracking tools, electronic diaries and investigator database solutions. Perceptive offers medical imaging services to rapidly and objectively assess the safety and efficacy of new drugs, biologics and medical devices in clinical trials. The IMPACT(TM) solution is Perceptive’s market-leading CTMS product with 25,000 users worldwide, and Perceptive’s INITIATOR(TM) trial management product targets the needs of Phase I units. For more information about Perceptive Informatics, visit www.perceptive.com.
About PAREXEL International
PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, medical marketing and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, Clinical Trial Management Systems (CTMS), Interactive Voice Response Systems (IVRS) and integration services. Headquartered near Boston, Massachusetts, PAREXEL operates in 56 locations throughout 43 countries around the world, and has over 6,215 employees. For more information about PAREXEL International visit www.PAREXEL.com.
This release contains “forward-looking” statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company’s actual future results may differ significantly from the results discussed in the forward- looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company’s recognition of revenue included in backlog; the Company’s dependence on certain industries and clients; the Company’s ability to win new business, manage growth and costs, and attract and retain employees; the Company’s ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company’s business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled “Risk Factors” of the Company’s Quarterly Report on Form 10-Q for the period ended December 31, 2006 as filed with the SEC on February 9, 2007, which “Risk Factors” discussion is incorporated by reference in this press release. The forward- looking statements included in this press release represent the Company’s estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.
PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of their respective business and are hereby acknowledged.
Contacts: Karen Wills, Vice President Corporate Marketing PAREXEL International Tel: +781-434-5301 Email: karen.wills@PAREXEL.com Rebecca Passo SHIFT Communications Tel: +617-681-1217 Email: rpasso@shiftcomm.com
PAREXEL International Corporation
CONTACT: Karen Wills, Vice President Corporate Marketing of PAREXELInternational, +1-781-434-5301, karen.wills@PAREXEL.com; or Rebecca Passoof SHIFT Communications, +1-617-681-1217, for PAREXEL InternationalCorporation
Web site: http://www.parexel.com/
